The European Biotech News Website
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Bioscience News - GEG Tech top picks
8.8K views |
+2 today
 Your new post is loading...
Your new post is loading...
Scoop.it!
BigField GEG Tech's insight:
What will happen to the scientists and the British science after the pro-referendum Brexit? Sciences et Avenir has asked Sir Venki Ramakrishnan, 2009 Nobel Prize in chemistry, new President for 6 months of the Royal Society. 
|
Scoop.it!
After the Brexit storm, the U.K. bioindustry may find itself becalmed, unable to commercialize its cellular therapeutics know-how. Seize the fiscal and regulatory oars!
BigField GEG Tech's insight:
The U.K. has ambitions to become the third largest global life science cluster by 2025,” stated Nick Gardiner, COO of the BioIndustry Association (BIA) at the recent bioProcessUK Conference in Newcastle. This goal could be achieved, attendees suggested, by various means. For example, many attendees agreed that the U.K. could attract and retain manufacturers of advanced therapy medicinal products (ATMPs). However, producing ATMPs such as cell and gene therapies is not an easy business. It requires investments in infrastructure, skilled people, and processes for efficient and profitable manufacturing.
|
At the present time, no one knows exactly what will happen once the UK leaves the EU, and regulatory affairs stand at the front line in interpreting what change Brexit will bring to the clinical trial process in Europe. Dr. Martine Dehlinger-Kremer of SynteractHCR shared what she expects.